Suspected anaphylactic reaction associated with microemulsion propofol during anesthesia induction.
Although rare, intraoperative anaphylaxis can lead to significant morbidity and mortality. Aquafol® (Daewon Pharmaceutical Co. Ltd., Seoul, Korea), a microemulsion propofol, was developed to eliminate lipid solvent-related adverse events, and was used in clinical anesthesia since 2009 with little data about severe side effects such as anaphylaxis. A healthy 16-yr-old male patient who had past medical history with two previous operations of no complications developed cardiovascular shock with generalized erythema following administration of microemulsion propofol during anesthesia induction. Intravenous injection of epinephrine and steroid rescued him. He remained in a stable state without any problems postoperatively and was discharged. Clinicians should consider this rare but serious complication during induction of anesthesia with propofol.
Department of Anesthesiology and Pain Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea.
Se Jin
SJ
Lee
Soon Im
SI
Kim
Bo Il
BI
Jung
Su Myung
SM
Lee
Mun Gyu
MG
Kim
Sun Young
SY
Park
Sang Ho
SH
Kim
Si Young
SY
Ok
D000293:Adolescent; D000707:Anaphylaxis / Q000139:chemically induced* / Q000188:drug therapy; D018686:Anesthetics, Intravenous / Q000008:administration & dosage* / Q000009:adverse effects; D001993:Bronchodilator Agents / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004655:Emulsions / Q000737:chemistry; D004837:Epinephrine / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D015742:Propofol / Q000008:administration & dosage* / Q000009:adverse effects
D018686:Anesthetics, Intravenous; D001993:Bronchodilator Agents; D004655:Emulsions; D005938:Glucocorticoids; D003907:Dexamethasone; D015742:Propofol; D004837:Epinephrine